布地奈德福莫特罗吸入治疗慢阻肺合并肺癌稳定期的疗效探讨

Efficacy of budesonide and formoterol inhalation on patients with stable chronic obstructive pulmonary disease and lung cancer

目的探讨布地奈德福莫特罗吸入治疗慢性阻塞性肺疾病(慢阻肺)合并肺癌稳定期患者的临床疗效。方法58例慢阻肺合并肺癌稳定期患者,随机分为实验组和对照组,各29例。对照组采用常规治疗,实验组采用布地奈德福莫特罗吸入治疗。比较两组患者治疗前后肺功能指标[第1秒用力呼气容积占预计值的百分比(FEV1%)、第1秒用力呼吸容积与用力肺活量的比值(FEV1/FVC)]及生活质量评分、慢性阻塞性肺疾病评估测试(CAT)评分。结果治疗前,两组FEV1%、FEV1/FVC水平比较差异无统计学意义(P>0.05);治疗后,实验组FEV1%(69.8±8.2)%、FEV1/FVC(67.6±12.1)%高于对照组的(63.5±7.9)%、(60.6±11.2)%,差异有统计学意义(P<0.05)。实验组生活质量评分(73.56±5.21)分高于对照组的(57.32±6.12)分,CAT评分(15.21±2.98)分低于对照组的(32.26±7.89)分,差异有统计学意义(P<0.05)。结论对慢阻肺合并肺癌稳定期患者应用布地奈德福莫特罗吸入治疗的效果明显,能明显改善患者的临床症状及肺功能指标,有效提升患者的生活质量。

Objective To discuss the clinical efficacy of budesonide and formoterol inhalation on patients with stable chronic obstructive pulmonary disease and lung cancer.Methods A total of 58 patients with stable chronic obstructive pulmonary disease and lung cancer were randomly divided into experimental group and control group,with 29 cases in each group.The control group received conventional treatment,and the experimental group received budesonide and formoterol inhalation treatment.Both groups were compared in terms of lung function indexes[forced expiratory volume in the 1st second as a percentage of the predicted value(FEV1%),forced expiratory volume in the 1st second/forced vital capacity(FEV1/FVC)]before and after treatment,quality of life score,and chronic obstructive pulmonary disease assessment test(CAT)score.Results Before treatment,there was no statistically significant difference in FEV1%and FEV1/FVC between the two groups(P>0.05).After treatment,FEV1%(69.8±8.2)%and FEV1/FVC(67.6±12.1)%in the experimental group were higher than(63.5±7.9)%and(60.6±11.2)%in the control group,AND the difference was statistically significant(P<0.05).The quality of life score(73.56±5.21)points of the experimental group was higher than(57.32±6.12)points of the control group,and the CAT score(15.21±2.98)points was lower than(32.26±7.89)points of the control group.All the differences were statistically significant(P<0.05).Conclusion Budesonide and formoterol inhalation has obvious effect on patients with stable chronic obstructive pulmonary disease and lung cancer,and can obviously improve the clinical symptom and lung function indicators,and effectively improve the quality of life of patients.